Wolverine Asset Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Wolverine Asset Management’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,187	Closed	-$51K	–	2625
2022 Q1	$51K	Sell	5,187 -45,165	-90%	-$443K	﹤0.01%	1504
2021 Q4	$491K	Sell	50,352 -7,004	-12%	-$68.6K	﹤0.01%	1018
2021 Q3	$560K	Sell	57,356 -5,170	-8%	-$50.4K	﹤0.01%	932
2021 Q2	$615K	Buy	62,526 +5,298	+9%	+$52.1K	﹤0.01%	827
2021 Q1	$571K	Buy	57,228 +54,228	+1,808%	+$557K	﹤0.01%	863
2020 Q4	$30K	Buy	+3,000	New	+$30.2K	﹤0.01%	1407

Other funds holding EUCR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

ECU

Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Wolverine Asset Management's EUCR Position: Q2 2022 in Review

Wolverine Asset Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q2 2022, closing a stake of 5,187 shares — an estimated $51K sold.

Wolverine Asset Management first reported a position in EUCR in Q4 2020 and held it in 6 quarters. The position peaked at $615K in Q2 2021. 37 funds tracked by Wall St. Rank hold EUCR as of Q2 2022.

Wolverine Asset Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Wolverine Asset Management sold 5,187 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q2 2022, an estimated $51K.
Wolverine Asset Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2020 and held it in 6 quarters.
Wolverine Asset Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $615K in Q2 2021.
37 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q2 2022.

Based on Wolverine Asset Management's 13F filing for Q2 2022, filed 3 Aug 2022.